ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment Notification of managers' transaction - Riad Sherif - July 2025 RSU vest

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, U.S.Fireside chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morgan European Healthcare Conference June 12; London, U.K.Riad Sherif, MD, Chief Executive Officer, will be attending. The Company will be available for one-on-one meetings dur

ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic NeuritisOCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular edema (DME)Licaminlimab (OCS-02) genotype-based development plan to drive a personalized medicine approach in dry eye disease (DED) aligned with FDA; first registrational trial initiation anticipated in 2H 2025Cas

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, BelgiumCompany update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America Healthcare ConferenceMay 13-15, 2025; Las Vegas, USAFireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT H.C. Wainwright Annual BioConnect at NasdaqMay 20, 2025; New York,

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage 1 of the Phase 3 DIAMOND progr

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register here. The event will provide an update on Oculis' portfolio of three innovative late-stage clinical candidates, offer further details on the recently disclosed ACUITY clinical results and outline the anticipated nex

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15 ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophth

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here. The event will provide an update on Oculis' portfolio of innovative late-stage clinical candidates, highlight recent clinical data and next steps, as well as discuss future development programs and business strategy. It will

S-8 - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

20-F - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

424B5 - Oculis Holding AG (0001953530) (Filer)

SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)

Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

H.C. Wainwright initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $28.00

Robert W. Baird initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $58.00

Pareto initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $23.00

Wedbush initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $27.00

ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipelineAppointment further expands Oculis' executive leadership team and bolsters U.S. presence ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chie

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah's joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations for global marketing applications including its first NDA submission to the U.S. FDA ZUG, Switzerland and BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3 trial (DIAMOND-2) of OCS-01 eye drops in Diabetic Macular Edema (DME) initiated as planned, in addition to the ongoing DIAMOND-1 Phase 3 trial initiated in late 2023World-renowned retina specialists, Professor Ramin Tadayoni, M.D., Ph.D. appointed as Chief Scientific Officer and Arshad M. Khanani, M.D., M.A., FASRS appointed as Chair of Oculis' Retina Scientific Advisory Board (SAB)Seasoned HR executive, Virginia R. Dean, appointed as Chief Human Resources Officer in Boston ZUG, Switzerland, a

Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME)Enrolled first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME)Cash and investments of $116.5 million adequately funded to deliver on key business and clinical milestones ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve e

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01's recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery propels Oculis into pre-commercial phase in anticipation of the Company's first US commercial launchIf approved, OCS-01 has the potential to become the first topical preservative-free eye

DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

SC 13G - Oculis Holding AG (0001953530) (Subject)

SC 13G/A - Oculis Holding AG (0001953530) (Subject)